AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02348372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A Placebo
Description: Matching size, shape and color
Study NCT02348372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863A Placebo
Description: Matching size, shape and color
Study NCT02348372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet
Study NCT02804867 — intervention group
Intervention type: PROCEDURE
Intervention: Online questionnaire and self-administered blood spot
Study NCT01573754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 100 mg by mouth twice weekly
Study NCT01573754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: 450 mL every 2 weeks
Study NCT04392830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ002 DS
Description: Administered orally
Study NCT04392830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Oral administration of 250 mg paracetamol
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Oral administration of 250 mg paracetamol
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Oral administration of 50 mg sulfasalazine
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: Oral administration of 50 mg sulfasalazine
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Oral administration of 120 mg fexofenadine
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fexofenadine
Description: Oral administration of 120 mg fexofenadine
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Oral administration of 40 mg valsartan
Study NCT03012763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan
Description: Oral administration of 40 mg valsartan
Study NCT03012763 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-caloric water
Description: Oral administration of 240 ml non-caloric water
Study NCT02348372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863A
Description: A round, biconvex, white film coated tablet
Study NCT04599907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roll-In Cohort: Single Application of N-SWEAT Patch
Description: Single Application of N-SWEAT Patch in both axillae for 10 subjects
Study NCT04599907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Randomized Cohort: Single Application of N-SWEAT Patch
Description: Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
Study NCT04599907 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Randomized Cohort: Single Application of Sham Patch
Description: Single Application of Sham Patch in both axillae for subjects randomized to the control group
Study NCT03012763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caloric drink
Description: Oral administration of 240 ml caloric drink
Study NCT03012763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: grapefruit juice
Description: Oral administration of 240 ml grapefruit juice
Study NCT01466517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alivium®
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Study NCT01466517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
Study NCT04739332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Newborn behavioral observations system
Description: The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
Study NCT04342988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cequa
Description: The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
Study NCT02187445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Description: To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
Study NCT00977795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Description: oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
Study NCT02864199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
Study NCT02864199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
Study NCT04630470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage therapy with lavender oil
Description: massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
Study NCT04630470 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: massage therapy with baby oil
Description: massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
Study NCT02579278 — intervention group
Intervention type: OTHER
Intervention: Blood sample (mrEMVI positive patient)
Description: Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
Study NCT02579278 — intervention group
Intervention type: OTHER
Intervention: Blood sample (mrEMVI negative patient)
Study NCT06276114 — intervention group
Intervention type: DEVICE
Intervention: Stent Underexpansion
Description: Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
Study NCT04684771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MYOSTIM®
Description: Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
Study NCT04684771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Bars with no active ingredient and the same flavor (chocolate and red fruits).
Study NCT00494208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone ester
Study NCT03134274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dip HBDA
Description: Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
Study NCT01612221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
Study NCT01612221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
Study NCT02872818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17β estradiol hemihydrate
Description: 4mg/kg/day for 20 days
Study NCT02872818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 50 mg/kg/day last 10 days
Study NCT02872818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: 1mg/kg/day last 10 days
Study NCT03146754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methodology
Description: No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
Study NCT03146754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methodology
Description: No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
Study NCT03098797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 40 mg daily subcutaneous injection for 12 weeks
Study NCT03098797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elamipretide
Description: 40 mg daily subcutaneous injection for 12 weeks
Study NCT03098797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: daily subcutaneous injection for 12 weeks
Study NCT03098797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily subcutaneous injection for 12 weeks
Study NCT04410315 — intervention group
Intervention type: OTHER
Intervention: Serum-lactate < 2,2 mmol/L
Description: Bloodgas analysis every hour from start surgery until recovery ward discharge
Study NCT04410315 — intervention group
Intervention type: OTHER
Intervention: Serum-lactate >/= 2,2 mmol/L
Description: Bloodgas analysis every hour from start surgery until recovery ward discharge
Study NCT00761397 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: 15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
Study NCT00761397 — intervention group
Intervention type: BEHAVIORAL
Intervention: Phone Call
Description: Phone call follow ups for 4 weeks after last radiation treatment
Study NCT00761397 — intervention group
Intervention type: OTHER
Intervention: Brochure
Description: Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
Study NCT00761397 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
Study NCT03090633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: Minimally invasive in-utero surgery
Study NCT04251962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: epidural solution containing bupivacaine 0.1% in normal saline
Study NCT04251962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
Study NCT02921750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber Gelling Fibre Dressing
Description: Gelling fibre dressing
Study NCT02921750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre
Description: Hydrofiber® Dressing with Strengthening Fibre
Study NCT00990067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg, single dose
Study NCT00990067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: 120 mg two doses 12h and 2h before MDMA
Study NCT00990067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: capsules identical to MDMA or duloxetine
Study NCT02638129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone HCl/Bupropion HCl ER
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
Study NCT02638129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone HCl/Bupropion HCl ER
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
Study NCT02638129 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets
Study NCT02638129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets
Study NCT03648554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulaglutide (TRULICITY®) 1.5 mg
Description: dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
Study NCT03648554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reinforced dietary monitoring
Description: moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
Study NCT03648554 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: reinforced dietary monitoring
Description: moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
Study NCT03099772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-IU
Description: Cognitive-behavioral therapy for intolerance of uncertainty
Study NCT04427137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 Stimulator, B70 Fluid-Cooled Coil
Description: Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
Study NCT00619164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 50 mg (tablet), taken orally, once a day.
Study NCT00619164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 100 mg (tablet), taken orally, once a day.
Study NCT00619164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: E5555, 200 mg (tablet), taken orally, once a day.
Study NCT00619164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally, once a day.
Study NCT04684875 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency Stylus
Description: Low power radiofrequency energy delivered to the posterior nasal nerve area
Study NCT02671019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guide to better alcohol habits
Description: A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
Study NCT02671019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guide to better alcohol habits
Description: A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
Study NCT00743288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Same as above
Study NCT00743288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT03464942 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
Study NCT03464942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
Study NCT00638209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin
Study NCT00638209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01325259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychologic assessment
Description: Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
Study NCT01325259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET
Description: intravenous injection of 4 MBq/kg of \[18F\]AV-45
Study NCT01325259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18-FDG PET
Description: intravenous injection of 100 to 120 MBq of FDG
Study NCT01325259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging
Study NCT03959904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small stitch
Description: Wound closure will be using small stiches or larger spaced stitches
Study NCT03959904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: A blood sample to look for biological markers of Hernia formation will be taken
Study NCT03959904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Sample
Description: A tissue sample will be taken to measure markers of wound healing.
Study NCT03959904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Score
Description: A pain score will be recorded following the surgical procedure.
Study NCT03959904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Score
Description: A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
Study NCT04263636 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification with bilateral trifocal diffractive IOLs
Description: Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
Study NCT04339010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercise
Description: The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
Study NCT04339010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypopressive exercise
Description: The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
Study NCT04339010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle contraction
Description: Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
Study NCT00610233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation ON
Description: deep brain stimulation in the ON state
Study NCT00610233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation OFF
Description: Urodynamic investigation with deep brain stimulation in the OFF state
Study NCT04631107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose1- A
Description: Oral administration at bedtime
Study NCT04631107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AD109 dose2- B
Description: Oral administration at bedtime
Study NCT04631107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo- C
Description: Oral administration at bedtime
Study NCT02012959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Study NCT04536961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment- BMS-986165-01
Description: Specified dose on specified days
Study NCT04536961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype BMS-986165
Description: Specified dose on specified days
Study NCT04536961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study NCT04536961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Specified quantity on specified days
Study NCT04351126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 Milligrams (mg)
Description: 0.2-0.6 mg/day of fludrocortisone is prescribed
Study NCT04351126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: 2.5 mg prescribed Vaginally twice daily
Study NCT04351126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: 2.5 mg prescribed Vaginally twice daily